{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T15:47:38Z","timestamp":1744991258242,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12185-024-03828-7","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T03:32:42Z","timestamp":1723001562000},"page":"639-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in coagulation potential over time after administration of recombinant activated factor VII in an emicizumab-treated hemophilia A patient with inhibitors"],"prefix":"10.1007","volume":"120","author":[{"given":"Mitsumasa","family":"Osuna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-2782","authenticated-orcid":false,"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"6","key":"3828_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535\u201344.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3828_CR2","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1160\/TH16-01-0049","volume":"116","author":"CE Walsh","year":"2016","unstructured":"Walsh CE, Jim\u00e9nez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016;116(Suppl 1):S10\u20137.","journal-title":"Thromb Haemost"},{"issue":"1","key":"3828_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","volume":"15","author":"E Berntorp","year":"2009","unstructured":"Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3\u201310.","journal-title":"Haemophilia"},{"issue":"21","key":"3828_CR4","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"3828_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","volume":"115","author":"Y Nakajima","year":"2022","unstructured":"Nakajima Y, Mizumachi K, Shimonishi N, Furukawa S, Yada K, Ogiwara K, et al. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients. Int J Hematol. 2022;115(4):489\u201398.","journal-title":"Int J Hematol"},{"issue":"8","key":"3828_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256317","volume":"16","author":"H Sarkadi","year":"2021","unstructured":"Sarkadi H, Cs\u0151re J, Veres DS, Szegedi N, Moln\u00e1r L, Gell\u00e9r L, et al. Incidence of and predisposing factors for pseudoaneurysm formation in a high-volume cardiovascular center. PLoS\u00a0One. 2021;16(8): e0256317.","journal-title":"PLoS\u00a0One"},{"issue":"11","key":"3828_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s13312-014-0530-9","volume":"51","author":"S Vora","year":"2014","unstructured":"Vora S, Ibrahim T, Rajadurai VS. Radial artery pseudoaneurysm in a neonate with hemophilia A. Indian Pediatr. 2014;51(11):921\u20133.","journal-title":"Indian Pediatr"},{"issue":"5","key":"3828_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MBC.0b013e32835e42aa","volume":"24","author":"EC Rodriguez-Merchan","year":"2013","unstructured":"Rodriguez-Merchan EC. Pseudoaneurysms in haemophilia. Blood Coagul Fibrinolysis. 2013;24(5):461\u20134.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"3828_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2516.2010.02434.x","volume":"17","author":"M Drew","year":"2011","unstructured":"Drew M, Yu JC, Michaels LA. Arterial pseudoaneurysms in haemophilia: conservative treatment with observation and factor replacement. Haemophilia. 2011;17(3):550\u20132.","journal-title":"Haemophilia"},{"issue":"6","key":"3828_CR10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/jth.14022","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16(6):1078\u201388.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3828_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/clpt.1994.80","volume":"55","author":"CM Lindley","year":"1994","unstructured":"Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55(6):638\u201348.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3828_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s12185-021-03108-8","volume":"113","author":"Y Nakajima","year":"2021","unstructured":"Nakajima Y, Tonegawa H, Noguchi-Sasaki M, Nogami K. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor. Int J Hematol. 2021;113(6):789\u201396.","journal-title":"Int J Hematol"},{"issue":"6","key":"3828_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12185-021-03095-w","volume":"113","author":"K Mizumachi","year":"2021","unstructured":"Mizumachi K, Tsumura Y, Nakajima Y, Koh K, Nogami K. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis. Int J Hematol. 2021;113(6):930\u20135.","journal-title":"Int J Hematol"},{"key":"3828_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620719860025","volume":"10","author":"H Kizilocak","year":"2019","unstructured":"Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019;10:1\u20139.","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"3828_CR15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/jth.15287","volume":"19","author":"M Ninivaggi","year":"2021","unstructured":"Ninivaggi M, de Laat-Kremers R, Tripodi A, Wahl D, Zuily S, Dargaud Y, et al. Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies. J Thromb Haemost. 2021;19(5):1372\u20138.","journal-title":"J Thromb Haemost"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03828-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T08:44:03Z","timestamp":1730105043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03828-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3828"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03828-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MO has no conflict of interest to disclose. YN has received a grant from Takeda Pharmaceutical Co. KO taught a course endowed by CSL Behring and has received personal fees from Chugai Pharmaceutical Co., Ltd. and CSL Behring. KN has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hoffmann-La Roche Ltd.; and grants and personal fees from Sysmex Co., Takeda Pharmaceutical Co., Sanofi S. A., CSL Behring Co., KM Biologics Co., Novo Nordisk A\/S, Bayer AG and is an inventor of patents relating to emicizumab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}